{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:44:42Z","timestamp":1791830682284,"version":"4.3.4"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["HSS Journal\u00ae: The Musculoskeletal Journal of Hospital for Special Surgery"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Obesity is a major modifiable risk factor in total hip arthroplasty (THA), associated with increased complications. While bariatric surgery has been the standard for massive weight loss, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purposes:<\/jats:title>\n                    <jats:p>We sought to answer 2 questions: (1) Are early postoperative complication risks different between THA patients using GLP-1 RAs versus prior bariatric surgery? (2) Do differences persist at mid-term follow-up?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the TriNetX Global Collaborative Network to identify adult patients (\u226518\u2009years) who underwent primary THA (current procedural terminology code 27130) between January 2015 and December 2025. Patients were divided into 2 cohorts: those with an active prescription for a GLP-1 RA (semaglutide, dulaglutide, liraglutide, tirzepatide, exenatide, albiglutide, or lixisenatide) within 18\u2009months prior to the index THA procedure (N\u2009=\u20096877) or those with a history of bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric banding, and biliopancreatic diversion) within 18\u2009months prior to the index THA procedure (N\u2009=\u20093960). Propensity-score matching (1:1) balanced cohorts on demographics and comorbidities. Outcomes included revision THA, dislocation\/instability, PJI, wound complications, emergency department (ED) visits, and readmission at 1 to 90\u2009days and 91\u2009days to 1\u2009year postoperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Within 90\u2009days, the GLP-1 RA cohort had lower risks of revision, PJI, ED visits, readmission, wound dehiscence, and dislocation. At mid-term follow-up, GLP-1 RA patients continued to show lower risks of PJI, readmission, and all-cause revision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Preoperative GLP-1 RA use was associated with lower early and mid-term complications compared to bariatric surgery, suggesting a potentially safer option for pre-THA weight optimization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>Level III: retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15563316261492267","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:19:36Z","timestamp":1791440376000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4435-4510","authenticated-orcid":false,"given":"Smit","family":"Brahmbhatt","sequence":"first","affiliation":[{"name":"Penn State College of Medicine, Hershey, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5144-4619","authenticated-orcid":false,"given":"Amal","family":"Mathew","sequence":"additional","affiliation":[{"name":"Penn State College of Medicine, Hershey, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Shoap","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics &amp; Rehabilitation, Penn State Milton S Hershey Medical Center, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics &amp; Rehabilitation, Penn State Milton S Hershey Medical Center, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Onggo JR Onggo JD de Steiger R Hau R. Greater risks of complications infections and revisions in the obese versus non-obese total hip arthroplasty population of 2 190 824 patients: a meta-analysis and systematic review. Osteoarthritis Cartilage. 2020;28(1):31-44. https:\/\/doi.org\/10.1016\/j.joca.2019.10.005","DOI":"10.1016\/j.joca.2019.10.005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Orringer M Palmer RC Ball JR Telang S Lieberman JR Heckmann ND. Effect of BMI on the risk of postoperative complications following total hip arthroplasty. Bone Joint J. 2025;107-B(5 suppl A):47-54. https:\/\/doi.org\/10.1302\/0301-620X.107B5.BJJ-2024-1098.R1","DOI":"10.1302\/0301-620X.107B5.BJJ-2024-1098.R1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Liu P Meng J Tang H et al. Association between bariatric surgery and outcomes of total joint arthroplasty: a meta-analysis. Int J Surg. 2025;111(1):1541-1546. https:\/\/doi.org\/10.1097\/JS9.0000000000002002","DOI":"10.1097\/JS9.0000000000002002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Feng Y Ju H Chen L Zhou Y. Impact of bariatric surgery on long term outcomes of patients undergoing joint arthroplasty: a meta-analysis. Obes Surg. 2025;35(7):2588-2601. https:\/\/doi.org\/10.1007\/s11695-025-07953-y","DOI":"10.1007\/s11695-025-07953-y"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Reytor-Gonz\u00e1lez C Frias-Toral E Nu\u00f1ez-V\u00e1squez C et al. Preventing and managing pre- and postoperative micronutrient deficiencies: a vital component of long-term success in bariatric surgery. Nutrients. 2025;17(5):741. https:\/\/doi.org\/10.3390\/nu17050741","DOI":"10.3390\/nu17050741"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Aaseth JO Alexander J. Postoperative osteoporosis in subjects with morbid obesity undergoing bariatric surgery with gastric bypass or sleeve gastrectomy. Nutrients. 2023;15(6):1302. https:\/\/doi.org\/10.3390\/nu15061302","DOI":"10.3390\/nu15061302"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Nuzzo A Czernichow S Hertig A et al. Prevention and treatment of nutritional complications after bariatric surgery. Lancet Gastroenterol Hepatol. 2021;6(3):238-251. https:\/\/doi.org\/10.1016\/S2468-1253(20)30331-9","DOI":"10.1016\/S2468-1253(20)30331-9"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Kubsad S Raftis DA Agarwal AR et al. No difference in revision rates up to 10 years following total hip arthroplasty in patients who had prior bariatric surgery when compared to patients who had class III obesity: a propensity matched analysis. J Arthroplasty. 2024;39(6):1399-1403.e1. https:\/\/doi.org\/10.1016\/j.arth.2024.02.065","DOI":"10.1016\/j.arth.2024.02.065"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Ryan SP Couch CG Duong SQ et al. Frank Stinchfield Award: does bariatric surgery prior to primary total hip arthroplasty really improve outcomes?. J Arthroplasty. 2022;37(7S):S386-S390. https:\/\/doi.org\/10.1016\/j.arth.2022.01.084","DOI":"10.1016\/j.arth.2022.01.084"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Moiz A Filion KB Tsoukas MA Yu OH Peters TM Eisenberg MJ. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025;138(6):934-940. https:\/\/doi.org\/10.1016\/j.amjmed.2025.01.021","DOI":"10.1016\/j.amjmed.2025.01.021"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Rosen CJ Ingelfinger JR. GLP-1 receptor agonists. N Engl J Med. 2026;394(13):1313-1324. https:\/\/doi.org\/10.1056\/NEJMra2500106","DOI":"10.1056\/NEJMra2500106"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Locatelli JC Costa JG Haynes A et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?. Diabetes Care. 2024;47(10):1718-1730. https:\/\/doi.org\/10.2337\/dci23-0100","DOI":"10.2337\/dci23-0100"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Mozaffarian D Agarwal M Aggarwal M et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine the American Society for Nutrition the Obesity Medicine Association and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. https:\/\/doi.org\/10.1016\/j.ajcnut.2025.04.023","DOI":"10.1016\/j.ajcnut.2025.04.023"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Aschen SZ Zhang A O\u2019Connell GM et al. Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes. Ann Surg. 2025;281(4):600-607. https:\/\/doi.org\/10.1097\/SLA.0000000000006614","DOI":"10.1097\/SLA.0000000000006614"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Ghebrehiwet-Kuflom J Mehta A Lim P Dahle S Isseroff RR. GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic cutaneous wound healing. J Invest Dermatol. 2025;145(12):2981-2988. https:\/\/doi.org\/10.1016\/j.jid.2025.08.045","DOI":"10.1016\/j.jid.2025.08.045"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Lee V Durkee SM Ponce BA Coutelle N Gerges P Lima D. Impact of glucagon-like peptide-1 receptor agonists on postoperative outcomes in arthroplasty: a systematic review. J Arthroplasty. 2025;40(12):3073-3079. https:\/\/doi.org\/10.1016\/j.arth.2025.07.015","DOI":"10.1016\/j.arth.2025.07.015"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Amen TB Ibrahim LI Gillinov SM et al. Glucagon-like peptide-1 agonists and common hand procedures: perioperative and postoperative risks and complications. J Hand Surg Am. 2025;50(11):1297-1303. https:\/\/doi.org\/10.1016\/j.jhsa.2025.08.004","DOI":"10.1016\/j.jhsa.2025.08.004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Palchuk MB London JW Perez-Rey D et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):ooad035. https:\/\/doi.org\/10.1093\/jamiaopen\/ooad035","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Kurtz SM Lau EC Ong KL Adler EM Kolisek FR Manley MT. Which clinical and patient factors influence the national economic burden of hospital readmissions after total joint arthroplasty?. Clin Orthop Relat Res. 2017;475(12):2926-2937. https:\/\/doi.org\/10.1007\/s11999-017-5244-6","DOI":"10.1007\/s11999-017-5244-6"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Schwarz JS Lygrisse KA Roof MA Long WJ Schwarzkopf RM Hepinstall MS. Early mid-term and late-term aseptic femoral revisions after THA: comparing causes complications and resource utilization. J Arthroplasty. 2021;36(10):3551-3555. https:\/\/doi.org\/10.1016\/j.arth.2021.05.041","DOI":"10.1016\/j.arth.2021.05.041"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Narla S Narla RR Corbett JA. JAAD CME part 1: mechanism of action of GLP-1 receptor agonists and potential pathways in skin health. J Am Acad Dermatol. 2026;2026:S0190-9622(26)00240-9. https:\/\/doi.org\/10.1016\/j.jaad.2026.01.088","DOI":"10.1016\/j.jaad.2026.01.088"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0000000000004657"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Chan YC Chuang SH Kuo YJ Lian YZ Chen YP. The association between glucagon-like peptide-1 receptor agonists and postoperative complications after arthroplasty: a systematic review and meta-analysis. J Arthroplasty. 2025;40(12):3080-3088.e7. https:\/\/doi.org\/10.1016\/j.arth.2025.06.083","DOI":"10.1016\/j.arth.2025.06.083"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Paccou J Tsourdi E Meier C et al. Bariatric surgery and skeletal health: a narrative review and position statement for management by the European Calcified Tissue Society (ECTS). Bone. 2022;154:116236. https:\/\/doi.org\/10.1016\/j.bone.2021.116236","DOI":"10.1016\/j.bone.2021.116236"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Shul C Hameed D Oster B et al. The impact of preoperative weight loss timing on surgical outcomes in total hip arthroplasty. J Arthroplasty. 2024;39(6):1424-1431. https:\/\/doi.org\/10.1016\/j.arth.2024.02.075","DOI":"10.1016\/j.arth.2024.02.075"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Jia IITT Bloomfield GC Chen MY et al. Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis. Surg Endosc. 2025;39(12):8580-8589. https:\/\/doi.org\/10.1007\/s00464-025-12086-5","DOI":"10.1007\/s00464-025-12086-5"}],"container-title":["HSS Journal\u00ae: The Musculoskeletal Journal of Hospital for Special Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15563316261492267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15563316261492267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15563316261492267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:46:13Z","timestamp":1791827173000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15563316261492267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":26,"alternative-id":["10.1177\/15563316261492267"],"URL":"https:\/\/doi.org\/10.1177\/15563316261492267","relation":{},"ISSN":["1556-3316","1556-3324"],"issn-type":[{"value":"1556-3316","type":"print"},{"value":"1556-3324","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"15563316261492267"}}